The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Salmon calcitonin: a review of current and future therapeutic indications
Abstract
Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“sCT has much higher biological potency in humans than hCT, and has, by far, been the most widely used preparation in clinical practice (33).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [33]
In the citing paper
“sCT was first introduced to the market in 1974 and was subsequently approved by the United States Food and Drug Administra-tion for use in the treatment of postmenopausal osteoporosis, hypercalcemia, and Paget's disease (33,165).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [33]
In the citing paper
“sCT was effective in inhibiting bone turnover, providing pain relief, and improving bone structure, healing osteolytic lesions and supporting the formation of normal lamellar bone (33).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [33]
In the citing paper
“A number of small studies of intranasal or subcutaneous use of sCT showed increases in bone density, reduced number of vertebral fractures, and an association with reduction of the risk of hip fracture (26, 33, 110, 139), whereas others found no bone effects (12).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [33]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475
Self-citation(2020) · Elsevier eBooks · doi:10.1016/c2015-1-01622-2 · Cited by 1,683
Meunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., Spector, T. D., Cannata, J., Balogh, A., Lemmel, E.-M., Pors-Nielsen, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa022436 · Cited by 1,638
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229 · cited 1×
“Similar subgroup analyses regarding the potential for non-vertebral fracture risk reduction have been used and validated as an appropriate analysis in other trials of osteoporosis trials on antiresorptive agents [50, 51].”
MethodSelf-citationChesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122 · cited 4×
“However the number of fractures in this study was small, and the main evidence for the antifracture efficacy of SCT-NS is derived from the PROOF study [28], which was a confirmative large-scale multicenter trial initiated in 1991.”
BackgroundMethodInfluentialSelf-citationPrevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 1×
“The existence of calcitonin receptors on osteoblasts has been suggested [21–24], and findings in some clinical trials have indicated a possible stimulatory effect on bone formation.”
BackgroundDelmas, P. D., Genant, H. K., Crans, G. G., Stock, J. L., Wong, M., Siris, E., & Adachi, J. D. (2003) · Bone · doi:10.1016/s8756-3282(03)00241-2 · Cited by 545 · cited 1×
“Similar subgroup analyses regarding the potential for non-vertebral fracture risk reduction have been used and validated as an appropriate analysis in other trials of osteoporosis trials on antiresorptive agents [50, 51].”
Method
Research works printed but not linked: 8
- Woodrow JP, Noseworthy CS, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS (2003) Calcitonin/calcitonin gene-related peptide protect the maternal skeleton from excessive resorption during lactation [abstract]. J Bone Miner Res 18(Suppl 2):S37
- Hoff A, Thomas M, Cote G (1998) Generation of a calcitonin knockout mouse model [abstract]. Bone 23:1062
- Voss A, Liese S, Priemel M, Catala-Lehnen P, Schilling AF, Mueldner C, Haberland M, Rueger JM, Emeson RB, Gagel RF, Schinke T, Amling M (2005) Uncovering the physiologic function of calcitonin using genetically modified mouse models [abstract]. J Bone Min Res (Suppl.):1162
- Chesnut CH, Richardson P, Mindeholm L (2002) Salmon calcitonin nasal spray (SCNS): effect on hip fractures in postmenopausal women [abstract]. Osteoporos Int 13(Suppl 1):128
- Olson M, Mindeholm L, Eriksen EF, Majumdar S, Azria M, Chesnut C (2006) Trabecular number as risk factor in osteoporosis and the role of nasal spray calcitonin (NS-CT) in its modification [abstract]. Osteoporos Int 17(Suppl 1):S12–S13
- Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, Tugwell P, Wells G (2000) Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD001983
- Gennari C, Agnusdei D (1988) Calcitonin in bone pain management. Curr Ther Res 44:712–722
- Gennari C, Chierichetti SM, Piolini M, Vibelli C, Agnusdei D, Civitelli R, Gonelli S (1985) Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study. Curr Ther Res 38:298–308
Cited by
Nutritional Value of Fish: Lipids, Proteins, Vitamins, and Minerals
Khalili Tilami, S., & Sampels, S. (2018) · Reviews in Fisheries Science & Aquaculture · doi:10.1080/23308249.2017.1399104 · Cited by 488
Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules
Chen, M.-C., Mi, F.-L., Liao, Z.-X., Hsiao, C.-W., Sonaje, K., Chung, M.-F., Hsu, L.-W., & Sung, H.-W. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.010 · Cited by 451
“Calcitonin, a peptide hormone of 32 amino acids, has been administered formany years to lower blood calcium and treat bone diseases, including osteoporosis and Paget's disease [146].”
BackgroundWitten, P. E., & Huysseune, A. (2009) · Biological Reviews · doi:10.1111/j.1469-185x.2009.00077.x · Cited by 362
“Salmon calcitonin is an established antiresorptive osteoporosis medication (Chesnut et al., 2008) and appears to have a similar effect in fish.”
BackgroundPEG-based thermosensitive and biodegradable hydrogels
Shi, J., Yu, L., & Ding, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.04.009 · Cited by 341
Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts
Moroz, E., Matoori, S., & Leroux, J.-C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.010 · Cited by 336
Metadata
- Authors
- Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L.
- Affiliations
- University of Washington (US)
- Novartis (Switzerland) (CH)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Chesnut, C. H.
- Venue
- Osteoporosis International
- Published
- 2007-12-11
- Volume
- 19
- Issue
- 4
- Pages
- 479-491
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2069365129
- Cited by
- 216
- References
- 106
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 8 · 2023: 10 · 2022: 17 · 2021: 7 · 2020: 15 · 2019: 10 · 2018: 12 · 2017: 15 · 2016: 12 · 2015: 7 · 2014: 11 · 2013: 14 · 2012: 9
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- salmon calcitonin, osteoporosis, Paget's disease, osteoarthritis, postmenopausal osteoporosis, bone quality, chondroprotection, metabolic bone disease
- MeSH terms
- Adult, Aged, Bone Resorption, Calcitonin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Middle Aged, Osteitis Deformans, Parathyroid Hormone, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Salmon calcitonin: a review of current and future therapeutic indications. https://app.cochat.ai/papers/10.1007/s00198-007-0490-1
- The paper
- Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008). Salmon calcitonin: a review of current and future therapeutic indications. Osteoporosis International. https://doi.org/10.1007/s00198-007-0490-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.